Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Rating Reiterat

HC Wainwright reiterated their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Free Report) in a report published on Tuesday morning, Benzinga reports. The brokerage currently has a $50.00 target price on the biotechnology company’s stock. Other analysts have also recently issued reports about the stock. Stephens initiated coverage on shares of Actinium Pharmaceuticals […]

Related Keywords

, Vanguard Group Inc , Sanders Morris Harris , Institutional Investors Weigh In On Actinium Pharmaceuticals , Actinium Pharmaceuticals Company Profile , News Ratings For Actinium Pharmaceuticals Daily , Cantor Fitzgerald , Actinium Pharmaceuticals , Creative Financial Designs Inc , Virtu Financial , Analyst Recommendations For Actinium Pharmaceuticals , Actinium Pharmaceuticals Price Performance , Brandywine Global Investment Management , Maxim Group , Actinium Pharmaceuticals Inc , Free Report , Moderate Buy , Get Free Report , Morris Harris , Financial Designs , Actinium Pharmaceuticals Daily ,